NDA 214200 · Pharmacosmos
Cosela
Trilaciclib Dihydrochloride · Intravenous
NovelBreakthrough therapyPriority reviewCDER novel approval, Feb 12, 2021: To mitigate chemotherapy-induced myelosuppression in small cell lung cancer
Last checked: Nov 20, 2026Latest source record: Aug 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Feb 12, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
0 Phase 3, 0 recruiting
FAERS reports
244
136 serious, 25 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2025.
COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). COSELA is a kinase inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. ( 1 )
Mechanism: Trilaciclib is a transient inhibitor of CDK 4 and 6. Hematopoietic stem and progenitor cells (HSPCs) in the bone marrow give rise to circulating neutrophils, RBCs, and platelets. HSPC proliferation is dependent on CDK4/6 activity.
Therapeutic areas: Oncology · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 12, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
- COSELA · TRILACICLIB DIHYDROCHLORIDE EQ 300MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trilaciclib Dihydrochloride" as an intervention, any sponsor and status, largest first.
G1 Therapeutics, Inc.Industry
NCT04887831 · 92 participants · Start Jun 4, 2021 · Primary completion Apr 7, 2023
Drug: Trilaciclib; Gemcitabine and 3 more · For: Urothelial Carcinoma; Bladder Cancer; Myelosuppression Adult and 2 more
Sites: Los Angeles, California; Whittier, California; Littleton, Colorado · 34 sites in all
- Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast CancerCompleted
G1 Therapeutics, Inc.Industry
NCT05112536 · 24 participants · Start Mar 3, 2022 · Primary completion Oct 31, 2022
Drug: Trilaciclib; Cylophosphamide and 4 more · For: Triple Negative Breast Cancer; Breast Cancer
Sites: Los Alamitos, California; Santa Monica, California; Whittier, California · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myelosuppression37
- off label use27
- dyspnoea19
- white blood cell count decreased19
- platelet count decreased18
- death16
- pneumonia15
- anaemia14
- performance status decreased14
- fatigue13
- nausea13
- infection12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2021 | 28 |
| 2022 | 67 |
| 2023 | 63 |
| 2024 | 18 |
| 2025 | 50 |
| 2026 | 17 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cosela (Trilaciclib Dihydrochloride)
2024 spending
$99K
Beneficiaries
n/a
12 claims
Per beneficiary
n/a
$1,552.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $80,223 |
| 2024 | $99,334 |
Part B: Cosela (Trilaciclib Dihydrochloride) · HCPCS J1448
2024 spending
$20.3M
Beneficiaries
797
6,219 claims
Per beneficiary
$25,532
2024 ASP limit $5.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $1,710,573 |
| 2022 | $12,092,253 |
| 2023 | $17,240,563 |
| 2024 | $20,349,383 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Pharmacosmos
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.